STATEMENT 2: What this study adds?
- A propofol population pharmacokinetic analysis performed on a large
dataset, originating from 107 children under the age of 2 years,
including a significant proportion of preterm and term neonates.
- Accounting for gestational and postnatal age as compared to
postmenstrual age, improves the description of propofol
pharmacokinetics in a (pre)term neonatal and infant population.
- The identification of an age effect on weight corrected V1 hints
towards changes in body composition not captured by overall weight.